Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mol Carcinog. 2024 Oct;63(10):1866-1873. doi: 10.1002/mc.23791. Epub 2024 Aug 2.
The tumorigenesis of intrahepatic cholangiocarcinoma (ICC) has been identified to be exceptionally involved in dysregulated Hippo/Yes-associated protein (YAP) signaling pathway (Hippo/YAP). Hippo/YAP functions as a master regulator engaged in a plethora of physiological and oncogenic processes as well. Therefore, the aberrant Hippo/YAP could serve as an Achilles' heel regarding the molecular therapeutic avenues for ICC patients. Herein, we comprehensively review the recent studies about the underlying mechanism of disrupted Hippo/YAP in ICC, how diagnostic values could be utilized upon the critical genes in this pathway, and what opportunities could be given upon this target pathway.
肝内胆管癌 (ICC) 的发生与失调的 Hippo/Yes 相关蛋白 (YAP) 信号通路 (Hippo/YAP) 密切相关。Hippo/YAP 作为一个主调控因子，参与了许多生理和致癌过程。因此，异常的 Hippo/YAP 可能成为 ICC 患者分子治疗途径的一个致命弱点。在此，我们全面回顾了关于 Hippo/YAP 在 ICC 中破坏的潜在机制的最新研究，以及如何利用该通路中的关键基因来评估诊断价值，以及如何利用该靶点途径。
